Literature DB >> 1554892

Prognostic potential of flow cytometric S-phase and ploidy prospectively determined in primary breast carcinomas.

S B Ewers1, R Attewell, B Baldetorp, A Borg, E Långström, D Killander.   

Abstract

In a prospective study of a consecutive breast cancer series accumulated in the period 1978-82, the S-phase fraction (SPF) and ploidy status were determined by flow cytometry performed on cell nuclei derived from samples of 580 primary tumors. Sixty percent of the tumors were non-diploid. After correction for debris the median SPF values were 7.3% overall, 12% for non-diploid tumors, and 2.9% for diploid tumors (2.6% when nodal subsets N2 and N3 and cases with metastases at presentation were excluded). The SPF values correlated both to tumor size (p = 0.008) and to the number of positive axillary lymph nodes (p = 0.03). At clinical follow-up in 1986, 467 unilateral breast cancer patients who had undergone radical treatment for cure could be evaluated with respect to the prognostic value of both the SPF value and ploidy status. The median duration of follow-up was then 59 months (range 2-90), and the median time-to-recurrence 24 months (range 2-69, n = 137). At follow-up in 1991, 201/467 of the patients had died, the median duration of follow-up being 50 months (range 2-126) for the decreased, and 119 (range 6-148) for the survivors. In multivariate analysis (Cox's proportional hazards models), the strongest independent predictors of distant recurrence-free survival (DRFS) were the number of positive axillary lymph nodes (p less than 0.0001), the debris-corrected SPF value alone (p = 0.003, versus p = 0.05 for uncorrected value), and ploidy status combined with the corrected SPF value (p = 0.0002). When age was taken into account, both the corrected SPF value and the ploidy-SPF combination were predictors of crude survival (p = 0.006 and p = 0.002, respectively). In univariate life-table analysis, the 5-year DRFS rate was 93% in node-negative (N0) cases with an SPF less than 7.3%, as compared to 80% in those with an SPF greater than or equal to 7.3% (p = 0.005). Among node-positive cases, the prognostic value of the SPF was confined to those with 1-3 positive nodes, the 5-year DRFS rate being 68% in cases with an SPF less than 7.3%, as compared to 40% in cases with an SPF greater than or equal to 7.3% (p = 0.01).(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1554892     DOI: 10.1007/bf01834639

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  42 in total

1.  Statistical evaluation of cell kinetic data from DNA flow cytometry (FCM) by the EM algorithm.

Authors:  B Baldetorp; M Dalberg; U Holst; G Lindgren
Journal:  Cytometry       Date:  1989-11

2.  Flow-cytometric DNA analysis in primary breast carcinomas and clinicopathological correlations.

Authors:  S B Ewers; E Långström; B Baldetorp; D Killander
Journal:  Cytometry       Date:  1984-07

3.  Association of DNA index and S-phase fraction with prognosis of nodes positive early breast cancer.

Authors:  D W Hedley; C A Rugg; R D Gelber
Journal:  Cancer Res       Date:  1987-09-01       Impact factor: 12.701

Review 4.  Practical breast carcinoma cell kinetics: review and update.

Authors:  J S Meyer; R W McDivitt; K R Stone; M U Prey; W C Bauer
Journal:  Breast Cancer Res Treat       Date:  1984       Impact factor: 4.872

5.  Human tumour cell kinetics using a monoclonal antibody against iododeoxyuridine: intratumour sampling variations.

Authors:  A C Begg; L Moonen; I Hofland; M Dessing; H Bartelink
Journal:  Radiother Oncol       Date:  1988-04       Impact factor: 6.280

6.  Cell proliferation and its relationship to clinical features and relapse in breast cancers.

Authors:  C Gentili; O Sanfilippo; R Silvestrini
Journal:  Cancer       Date:  1981-08-15       Impact factor: 6.860

7.  Evaluation of flow cytometric data of human tumours. Correction procedures for background and cell aggregations.

Authors:  H P Beck
Journal:  Cell Tissue Kinet       Date:  1980-03

8.  Nuclear DNA content and prognosis in human breast cancer: a static cytophotometric study.

Authors:  J Harvey; N de Klerk; I Berryman; G Sterrett; M Byrne; J Papadimitriou
Journal:  Breast Cancer Res Treat       Date:  1987       Impact factor: 4.872

9.  Cytometric characterization and clinical course of breast cancer diagnosed in a population-based screening program.

Authors:  T Hatschek; G Fagerberg; O Stål; S Sullivan; J Carstensen; O Gröntoft; B Nordenskjöld
Journal:  Cancer       Date:  1989-09-01       Impact factor: 6.860

10.  Indicators of prognosis in node-negative breast cancer.

Authors:  H Sigurdsson; B Baldetorp; A Borg; M Dalberg; M Fernö; D Killander; H Olsson
Journal:  N Engl J Med       Date:  1990-04-12       Impact factor: 91.245

View more
  3 in total

1.  Prognostic significance of flow cytometric DNA analysis and estrogen receptor content in breast carcinomas--a 10 year survival study.

Authors:  S B Ewers; R Attewell; B Baldetorp; A Borg; M Fernö; E Långström; D Killander
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

2.  S-phase fraction identifies high-risk subgroups among DNA-diploid breast cancers.

Authors:  H Romero; J Schneider; J Burgos; J Bilbao; F J Rodriguez-Escudero
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

3.  Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer?

Authors:  P Hietanen; C Blomqvist; V M Wasenius; E Niskanen; K Franssila; S Nordling
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.